At the Right Dose: Personalized (N-of-1) dosing for precision oncology

The objective of oncology therapeutics, especially in the age precision medicine, is to give right drug(s) patient at time. Yet, a major challenge finding dose for each patient. Determining safe and efficacious doses treatments, novel combination therapies, can be challenging. Moreover, traditionally, dosing cancer drugs based on giving same (a flat dose) or surface area/weight. But patients’ ability tolerate influenced by additional factors including, but not limited age, gender, race, co-morbidities, organ function, metabolism. Herein we present evidence that, era targeted drugs, individualized drug determined starting reduced using intra-patient escalation yield effective personalized combinations approved that have previously undergone formal phase I trials also optimize tested regimens.